Drug Database
TC

Tc 99m nofetumomab merpentan (Verluma)

✓ Approved

Poniard Pharmaceuticals · Small Molecule · Small Molecule

What is Tc 99m nofetumomab merpentan?

Tc 99m nofetumomab merpentan is a small molecule developed by Poniard Pharmaceuticals. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesVerluma
CompanyPoniard Pharmaceuticals
Drug ClassSmall Molecule, Imaging Agents
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Poniard Pharmaceuticals

Therapeutic Indications

Tc 99m nofetumomab merpentan is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Small cell lung cancer recurrent✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedCancers2026-10-16

Thyroid Cancer Incidence in North-East Spain, 2002-2021: A Population-Based Study.

Ayala-Conte Maria M, Basté Neus N, Trallero Jan J, Sanvisens Arantza A et al.

Background/Objectives: The incidence of thyroid cancer (TC) has increased worldwide over recent decades, particularly for well-differentiated histological subtypes, a trend largely attributed to overdiagnosis. Given potential geographical differences, this study analyzed TC incidence and temporal trends in the province of Girona, Spain, between 2002 and 2021. Methods: We conducted a cross-sectional study using data from the Girona Cancer Registry. Crude incidence rates (CRs), age-standardized incidence rates using the 2013 European (ASRe) and the 1960 World (ASRw) standard populations were calculated per 100,000 person-years. Temporal trends were assessed via the annual percentage change (APC) using generalized linear models. Results: A total of 998 incident TC cases were identified. Most patients were women (78.0%), with a median age at diagnosis of 48 years. Papillary TC was the predominant histological subtype (81.7%), and 70.6% of cases were diagnosed at Stage I. The overall ASRe was 6.8 and ASRw was 5.5, with incidence rates 3-4 times higher in women than in men. Overall, TC incidence increased significantly (APC: 2.7%), driven by increases in the 35-44 and ≥55 age groups, papillary histology, and early-stage disease (Stages I-II). Conclusions: The rise in TC incidence in Girona over the last two decades has been largely driven by Stage I papillary tumors, in both sexes, supporting a potentially substantial contribution of overdiagnosis. However, the concurrent increase in Stage II disease warrants continued surveillance, as it may reflect additional risk factors.

PMID 42882840
Read full article →
PubMedCancers2026-10-16

Hospital-Based Incidence Trends of Thyroid Cancer in Poland: Temporal Trends, Regional Disparities and Demographic Characteristics Based on a Nationwide Hospital Discharge Database (2012-2024).

Szydlarska Dorota D, Lewtak Katarzyna K, Ciechomska Marta Zuzanna MZ, Poznańska Anna A et al.

Background: Thyroid cancer (TC) is the most common endocrine malignancy, with a steadily increasing incidence observed worldwide. However, temporal trends and demographic patterns may vary across populations. Objectives: To assess hospital-based incidence rates, demographic characteristics, and selected epidemiological patterns of TC in Poland between January 2012 and December 2024. Material and Methods: This population-based, retrospective study utilized hospitalization records of TC patients in Poland obtained from the Nationwide General Hospital Morbidity Study. Only first-time hospitalizations in the study period with reported primary or secondary diagnoses of TC were included in the study. Results: The study cohort included 60,604 patients, and the mean annual hospital-based incidence rate was 12.2 per 100,000 inhabitants (95% CI: 11.0-13.4). The hospital-based incidence rate decreased from 15.2 in 2012 to 9.8 per 100,000 in 2020, followed by a marked increase, peaking to 16.6 per 100,000 in 2024. Women constituted 82.2% of cases, indicating a strong sex-related disparity. The mean age at diagnosis was 51.1 years (SD: 15.9). The mean age at diagnosis was 51.1 years (SD: 15.9), and a greater proportion of hospitalized thyroid cancer patients were urban than rural residents (67.4% vs. 32.6%). Marked regional variation was observed, with the highest rates recorded in selected northern and central voivodeships. Conclusions: TC hospitalization hospital-based incidence rates in Poland showed significant temporal variability, with the lowest rate in 2020, which may reflect disruptions in healthcare access during the COVID-19 pandemic and a possible diagnostic catch-up effect in subsequent years. Regional disparities may suggest the potential influence of environmental, socioeconomic, or healthcare-related factors.

PMID 42882820
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

LaVO4/Bi2O2S S-Scheme Heterojunction Driving Highly Efficient Photocatalytic Degradation of Tetracycline Antibiotics.

Chen Dongdong D, Zeng Yuhao Y, Zhang Yang Y, Cai Fengli F et al.

The rational design and fabrication of semiconductor photocatalysts possessing high intrinsic activity are pivotal for the remediation of tetracycline (TC)-contaminated aqueous streams. Herein, we synthesized a LaVO4/Bi2O2S heterostructure and comprehensively interrogated its physicochemical attributes through a synergistic suite of techniques-X-ray diffraction (XRD), N2 adsorption/desorption isotherms, Fourier-transform infrared spectroscopy (FT-IR), UV-Vis diffuse reflectance spectroscopy (UV-Vis DRS), field-emission scanning and transmission electron microscopy (FE-SEM/TEM), X-ray photoelectron spectroscopy (XPS), steady-state photoluminescence (PL), and photoelectrochemical measurements. These analyses collectively revealed that the LVO/BOS composite with an equal mass ratio of LaVO4 and Bi2O2S manifested pronounced visible-light harvesting, markedly suppressed charge-carrier recombination, and accelerated interfacial charge transfer, as evidenced by enhanced photocurrent response and reduced PL intensity relative to the constituent LaVO4 and Bi2O2S phases. Consequently, under simulated solar irradiation, LVO/BOS achieved a TC degradation efficiency of ≈89% within 90 min, outperforming bare LaVO4 (41%) and Bi2O2S (44%). The corresponding apparent first-order rate constant (k ≈ 0.0214 min-1) exceeded those of LaVO4 (0.0031 min-1) and Bi2O2S (0.0053 min-1) by factors of 6.90 and 4.04, respectively. Radical-scavenging assays coupled with electron-spin-resonance (ESR) spectroscopy identified superoxide (•O2-) as the dominant reactive oxygen species driving TC mineralization. Guided by the experimentally determined band alignments and the observed preferential preservation of high-potential holes in LaVO4 and high-energy electrons in Bi2O2S, an S-scheme (step-scheme) heterojunction mechanism was postulated to rationalize the superior photocatalytic performance. This work underscores the strategic merit of S-scheme LaVO4/Bi2O2S heterostructures as robust, visible-light-driven platforms for the abatement of refractory organic pollutants.

PMID 42883311
Read full article →
PubMedBiology2026-10-16

Acute Neuromuscular Responses and Interlimb Asymmetry Following 5 km and Half-Marathon Running in Recreational Runners.

Kuna Danijela D, Šušnjara Petar P, Findrik Klara K

Acute neuromuscular responses to running may vary according to exercise duration and physiological demands. This study compared changes in vastus medialis contractile properties, quadriceps maximal voluntary isometric contraction (MVIC), and interlimb asymmetry following 5 km and half-marathon running trials. Twenty-eight male recreational runners (36.96 ± 11.35 years) completed both trials 10 days apart. Maximal radial displacement (Dm), contraction time (Tc), and contraction velocity (Vc) were assessed using tensiomyography, while quadriceps MVIC was assessed using isometric dynamometry before and after each trial. Absolute interlimb asymmetry and its direction were also analysed. The unadjusted analysis showed a greater pre-to-post increase in Dm following the half-marathon; however, the effect of the running trial on post-running Dm was not significant after adjustment for baseline Dm. Tc and MVIC decreased after both trials, whereas Vc increased, with no significant running trial × time interactions for these outcomes. TMG- and MVIC-derived absolute interlimb asymmetry remained unchanged. Acute post-running responses differed according to the neuromuscular characteristic assessed rather than consistently according to running distance. Changes in contractile properties and maximal force-generating capacity were not accompanied by a systematic increase in the magnitude of between-leg differences.

PMID 42883355
Read full article →
PubMedWorld journal of surgical oncology2026-10-16

Near-infrared fluorescence imaging for ureteral and sentinel lymph node mapping in gynecological minimally invasive surgery: a review of fluorophores and domestic laparoscopic systems.

Chen Tongxin T, Li Haili H

As laparoscopic techniques continue to advance, intraoperative tissue visualization has become increasingly important. In gynecological oncology, sentinel lymph node (SLN) mapping remains a critical procedure for assessing lymph node metastasis and guiding lymphadenectomy. Meanwhile, iatrogenic ureteral injury, although rare, can have severe consequences. Thus, achieving rapid, reliable, and cost-effective intraoperative visualization of both SLNs and the ureters during laparoscopy poses a significant clinical challenge. Near-infrared fluorescence (NIRF) imaging has emerged as a promising solution, using various fluorophores such as methylene blue (MB), indocyanine green (ICG), and technetium-99m (99mTc) to enable clear visualization of living tissues. However, a comprehensive summary of the advantages and limitations of these fluorophores is lacking. This article reviews the efficacy of different fluorophores for SLN and ureteral mapping and discusses recent advances in domestic fluorescence laparoscopic systems.

PMID 42881460
Read full article →
PubMedCancers2026-10-16

Multi-Scale MRI, Radiology Reports, and Blood Biomarker-Guided Multimodal Deep Learning for Predicting Postoperative Recurrence in Cervical Cancer: A Multicenter Study.

Wu Yiyang Y, Ai Yao Y, Zhang Yangyang Y, Zhang Long L et al.

Objectives: Cervical cancer (CC) remains a leading cause of cancer-related morbidity and mortality among women worldwide, with postoperative recurrence posing a major challenge to long-term survival. Multimodal data integration, including imaging, textual, and clinical information, holds significant potential for enhancing prognostic prediction. This study aims to develop and validate a multimodal, multi-scale deep learning (DL) model for predicting recurrence in operable CC patients. Methods: This multicenter retrospective study included 445 operable CC patients with preoperative MRI and corresponding radiology reports from three institutions. A Multi-Scale Model (MSM) combining ConvNeXt and dual-path Vision Transformer (ViT) was developed. Textual features extracted from radiology reports using BERT were fused with imaging and clinical data to construct a multimodal network (MSM-TC). Model interpretability was enhanced using SHapley Additive exPlanations (SHAP) and attention visualization. Results: The MSM integrating ConvNeXt and ViT achieved receiver operating characteristic curve (AUC) values of 0.944, 0.837, and 0.681 in the training, internal validation, and external validation cohorts, respectively. Incorporating textual data (MSM-T) further improved performance (AUCs: 0.902, 0.860, and 0.742). The final multimodal model (MSM-TC) integrating imaging, textual, and clinical data demonstrated the highest predictive accuracy with AUCs of 0.930, 0.860, and 0.798 across training, internal validation, and external validation cohorts, respectively. Kaplan-Meier analysis confirmed that the model-derived risk score effectively stratified patients into high- and low-risk groups. Conclusions: Our multimodal, multi-scale DL framework robustly predicts recurrence and survival in operable CC patients, supporting its potential for individualized prognostic assessment and future clinical translation.

PMID 42882769
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Tc 99m nofetumomab merpentan